Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, ambulatory, male or female volunteers 16-40 years of age;~* Body mass index 18.0 to 30.0 kg/m\^2 inclusive;~* Scheduled to undergo surgical removal of at least 2 mandibular partial or full bony impacted third molars. Up to two maxillary third molars may be removed regardless of impaction level. Supernumerary teeth present may also be removed at the discretion of the oral surgeon;~* Mandibular molars must demonstrate modified Demirjian root classification stage D, E, F, G or H;~Exclusion Criteria:~* History of hypersensitivity to naproxen sodium, ibuprofen, nonsteroidal anti-inflammatory drugs (NSAIDS), aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the investigational products;~* Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;~* Relevant concomitant disease such as asthma (exercise induced asthma is permitted)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Naproxen Sodium (Aleve, BAY117031) (Type: EXPERIMENTAL): Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
- Ibuprofen (Advil) (Type: ACTIVE_COMPARATOR): Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
- Placebo (Type: PLACEBO_COMPARATOR): Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).